What is Lifesci Capital's Forecast for AVBP FY2025 Earnings?

ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) - Analysts at Lifesci Capital decreased their FY2025 EPS estimates for ArriVent BioPharma in a research note issued to investors on Monday, June 23rd. Lifesci Capital analyst S. Slutsky now anticipates that the company will earn ($3.99) per share for the year, down from their previous forecast of ($3.97). The consensus estimate for ArriVent BioPharma's current full-year earnings is ($2.74) per share. Lifesci Capital also issued estimates for ArriVent BioPharma's FY2026 earnings at ($4.03) EPS.

ArriVent BioPharma (NASDAQ:AVBP - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($1.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($1.24).

Other equities research analysts have also issued research reports about the stock. HC Wainwright increased their price objective on shares of ArriVent BioPharma from $39.00 to $40.00 and gave the stock a "buy" rating in a research report on Wednesday, May 14th. Guggenheim reissued a "buy" rating and issued a $45.00 price objective on shares of ArriVent BioPharma in a research report on Tuesday, June 24th. Wall Street Zen lowered shares of ArriVent BioPharma from a "hold" rating to a "strong sell" rating in a research report on Thursday, May 22nd. Jones Trading began coverage on shares of ArriVent BioPharma in a report on Tuesday, May 20th. They set a "buy" rating and a $40.00 price target for the company. Finally, B. Riley began coverage on shares of ArriVent BioPharma in a report on Thursday, March 20th. They set a "buy" rating and a $37.00 price target for the company. One analyst has rated the stock with a sell rating, six have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, ArriVent BioPharma currently has a consensus rating of "Moderate Buy" and an average target price of $40.00.

ArriVent BioPharma Stock Up 0.4%

Shares of ArriVent BioPharma stock traded up $0.10 during trading hours on Thursday, hitting $22.91. The company's stock had a trading volume of 876,062 shares, compared to its average volume of 221,050. ArriVent BioPharma has a 1-year low of $15.47 and a 1-year high of $36.37. The business has a fifty day moving average of $21.66 and a 200 day moving average of $22.94. The company has a market capitalization of $783.75 million, a PE ratio of -6.08 and a beta of 1.26.

Institutional Investors Weigh In On ArriVent BioPharma

Large investors have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC grew its holdings in ArriVent BioPharma by 773.8% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,599 shares of the company's stock valued at $43,000 after purchasing an additional 1,416 shares in the last quarter. Virtus ETF Advisers LLC bought a new position in ArriVent BioPharma during the 4th quarter valued at $73,000. KLP Kapitalforvaltning AS bought a new position in ArriVent BioPharma during the 4th quarter valued at $83,000. Jane Street Group LLC bought a new position in ArriVent BioPharma during the 1st quarter valued at $189,000. Finally, New York State Common Retirement Fund boosted its stake in ArriVent BioPharma by 34.6% during the 4th quarter. New York State Common Retirement Fund now owns 7,783 shares of the company's stock valued at $207,000 after acquiring an additional 2,000 shares during the last quarter. 9.48% of the stock is owned by institutional investors and hedge funds.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.